

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 15, 2002 (use as many sheets as necessary)				Complete if Known		RECEIVED FEB 15 PM 02
Applicant Number				09/807,603		
Filing Date				04/16/2001		
First Named Inventor				Satoru Todo		
Group Art Unit				1614		
Examiner Name				Brian Yong S KOWN		
Attorney Docket Number				067242-0148		

[illegible]

Examiner Signature		Date Considered	10-17-02
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 15, 2002 (use as many sheets as necessary)				Applicati n Number	09/807,603
				Filing Dat	04/16/2001
				First Named Inv nt r	Satoru Todo
				Group Art Unit	1614
				Examiner Name	Brian Yong S KOWN
Sheet	2	of	2	Attorney Docket Number	067242-0148

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
6	17	JENNIFER DALEY et al, "Validating Risk-Adjusted Surgical Outcomes: Site Visit Assessment of Process and Structure", J. Am. Coll. Sugr., 185(4):353-364 (1997), Elsevier Science, Inc..		
6	18	SATORU TODO et al, "Attenuation of Ischemic Liver Injury by Augmentation of Endogenous Adenosine", Transplantation, 63(2):217-223 (1997), Williams & Wilkins.		
6	19	NAOKI ISHIZAKI et al. "Comparison of Various Lazaroid Compounds for Protection Against Ischemic Liver Injury", Transplantation, 63(2):202-208 (1997), Williams & Wilkins.		
6	20	KAORU KOIKE et al, "Intestinal Ischemia and Type II Phospholipase A ₂ : Preliminary Report", Department of Emergency and Critical Care Medicine , Japan , p. 823(1995).		
6	21	KAORU KOIKE et al., "Intestinal Ischemia and Type II Phospholipase A ₂ : Preliminary Report", Japan, p. 823 (1995).		
6	22	ROBERTA E. SONNINO et al, "Phospholipase A ₂ Secretion During Intestinal Graft Ischemia", Digestive Diseases and Sciences, 42(5):972-981 (1997) Plenum Publishing Corporation.		
6	23	LEON J. DE WINDT et al., "Phospholipase A ₂ -mediated Hydrolysis of Cardiac Phospholipids: The Use of Molecular and Transgenic Techniques", Molecular and Cellular Biochemistry 180:65-73 (1998) Kluwer Academic Publishers, printed in the Netherlands.		
6	24	JUN TAKASAKI et al., "Antibodies Against Type II Phospholipase A ₂ Prevent Renal Injury Due to Ischemia and Reperfusion in Rats", FEBS Letters, 440:377-381 (1998) Federation of European Biochemical Societies.		
6	25	CAROL A. SARGENT et al., "Effect of the Phospholilphase A ₂ Inhibitors Quinacrine and 7,7-Dimethyleicosadienoic Acid in Isolated Globaly Ischemic Rat Hearts", The Journal of Pharmacology and Experimental Therapeutics, 262(3):1161-1167 (1992), The American Society for Pharmacology and Experimental Therapeutics.		
6	26	YOSHIRO SHIMIZU, "Nafamostat Mesilate Rinse Solution – A New Strategy To Prevent Warm Ischemia-Reperfusion Injury In Canine Pancreas Autotransplantation", J. Kyoto Pref. Univ. Med. 107(4), pp. 483-497 (1998).		

Examiner Signature		Date Considered	10-12-02
--------------------	--	-----------------	----------

*EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.